Impact Factor
4.33
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
6.45
2,883 total citations
h5-index
49
h5 depth signal
Cited share
88.9%
440 of 495
Total citations
2,883
Citation footprint
Metric signal
7.23
External metric anchor
Self-citation
6.2%
179 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
China
1,347
United States
153
Iran
102
Japan
66
India
63
Citing Fields of Research
Human Reproduction
986
Reproductive Health
687
Oncology
531
Noncoding RNA
225
Cancer & Development
215
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,492
Articles tracked across the journal lifetime
Indexed publication set
495
440 cited publications
Last 12 months
481
40.1 publications/month
Open access share
100.0%
481 OA publications in the last year
Leading citing country
China
1,347 citing publications
Leading citing field
Human Reproduction
986 citing publications
Latest tracked publication
17 October 2026
10 recent records available
Coverage & Indexing History
v7, 2014-
v1, 2008-
Active Coverage
Research Focus & Classification
Indexed Subjects
Human Reproduction
Broad Categories
Gynecology
Reproductive Medicine
Human Reproduction
MeSH Descriptors
Genital Diseases, Female
Ovarian Diseases
Ovary
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
02
DOI 10.1186/s13048-026-02295-4
Open DOI
MicroRNA-197-3p counteracts chemoresistance in ovarian cancer via collagen type IV alpha 6 inhibition
Background: Collagen type IV alpha 6 (COL4A6) is overexpressed in ovarian cancer, where its elevated levels contribute to tumor progression, chemoresistance, and poor clinical outcomes. Although dysregulation of microRNAs (miRNAs) is wel...
03
DOI 10.1186/s13048-026-02303-7
Open DOI
LncRNA RBMS3-AS3 promotes ovarian cancer progression by regulating QKI and RBFOX2
04
05
06
DOI 10.1186/s13048-026-02310-8
Open DOI
Long non-coding RNA ATP6V1B1-AS1 promotes ovarian cancer progression through targeting MAP3K3/p38 MAPK pathway
07
DOI 10.1186/s13048-026-02308-2
Open DOI
Macrophage polarization in ovarian inflammaging: mechanisms, mediators, and therapeutic targets
08
DOI 10.1186/s13048-026-02292-7
Open DOI
Novel follitropin delta dosing regimen during in vitro fertilisation using a progestin protocol and freeze-all strategy: a propensity score matching cohort study
Background: Follitropin delta, a recombinant Follicle-stimulating hormone (FSH) with higher biopotency due to its human cell line origin, is approved with an individualised dosing algorithm for GnRH antagonist protocols with fresh transf...
09
DOI 10.1186/s13048-026-02285-6
Open DOI
GnRH antagonist‑free late follicular phase ovarian stimulation versus an early follicular GnRH antagonist regimen in normo-ovulatory women undergoing freeze-all IVF/ICSI: a randomized controlled trial
Background: Conventional ovarian stimulation for in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) treatment begins in the early follicular phase and requires gonadotrophin-releasing hormone (GnRH) analogs to prevent p...
10
DOI 10.1186/s13048-026-02293-6
Open DOI
Cyclophosphamide as a reproductive hazard: disrupted riboflavin metabolism and circadian rhythms drive ovarian decline
Bibliographical & Catalog Notes
Description based on: 1:1 (1 Oct. 2008); title from PDF caption (publisher's Web site, viewed Oct. 15, 2008).
Articles added on an individual basis as accepted.
Mode of access: World Wide Web.